Clinical Trials Directory

Trials / Completed

CompletedNCT01573403

Efficacy and Safety of DLBS2411 in Healthy Volunteers

Effect of DLBS2411 on Gastric pH Regulation in Healthy Volunteers : Comparison With Placebo

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
54 (actual)
Sponsor
Dexa Medica Group · Industry
Sex
Male
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

This is a 3-arm, double-blind, randomized, controlled, parallel and dose ranging clinical study for 3 days of therapy to investigate the effect of DLBS2411 in gastric pH regulation as well as its safety in healthy volunteers. DLBS2411 has similar mechanism of action with proton-pump inhibitors (PPIs). However, it is hypothetically more potential than PPIs in suppressing gastric acid as our previous preclinical studies with DLBS2411 have proven its effects not only on the activity of H+/K+ ATPase, the enzyme that regulates proton pump in stomach, but also on its gene expression. It is hypothesized that DLBS2411 may benefit on gastric pH regulation in healthy volunteers.

Detailed description

There will be 3 groups of treatment; each group will consist of 18 subjects with the treatment regimens : * Treatment I : 1 caplet of DLBS2411 250 mg and 1 placebo caplet of DLBS2411, once daily * Treatment II : 2 caplets of DLBS2411 250 mg, once daily * Treatment III : 2 placebo caplets of DLBS2411, once daily Clinical examination to evaluate the investigational drug's efficacy will be performed by a 24-hour-gastric pH monitoring after the first dose of study drug administration. Besides, the pH of the gastric fluid will also be measured at the end of study (Day 3 of treatment). Safety examination will be performed at baseline and at end of study. The occurrence of adverse event will be observed during the study. All subjects will be under direct supervision of a medical doctor during the study period.

Conditions

Interventions

TypeNameDescription
DRUGDLBS24111 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
DRUGDLBS24112 caplets of DLBS2411 @250 mg, once daily
DRUGPlacebo DLBS24112 placebo caplets of DLBS2411, once daily

Timeline

Start date
2012-04-01
Primary completion
2012-12-01
Completion
2013-01-01
First posted
2012-04-09
Last updated
2013-02-13

Locations

1 site across 1 country: Indonesia

Source: ClinicalTrials.gov record NCT01573403. Inclusion in this directory is not an endorsement.